FRANKFURT, Oct 10 (Reuters) - Merck KGaA's Rebif multiple-sclerosis drug is not superior to rival Teva's Copaxone, a study obtained by Reuters on Wednesday showed. "The number of events (relapses) was ...

CAMBRIDGE, MA – Sept. 11, 2009 – Data from an observational phase IV study of 499 patients entitled The Swiss MS Skin Project show that multiple sclerosis (MS) patients taking AVONEX (interferon ...